Allergic Rhinitis with Nonnasal Symptoms:
Intranasal Steroids Revisited
Release date: January 2008
Expiration date: December 31, 2008
Estimated time to complete activity: 2.25 hours
Target Audience
This activity has been designed to meet the educational needs of physicians involved in the management of patients with allergic rhinitis.
Statement of Need/Program Overview
Several studies suggest that the prevalence of allergic diseases have increased worldwide in recent years. The notion of the “Unified Airway” has reinforced the concept that allergic rhinitis (AR) is frequently associated with several comorbidities, including allergic conjunctivitis, asthma, chronic sinusitis, and sleep disturbances. The purpose of this educational activity is to review the pathophysiology and treatment of AR and its nonnasal symptoms. New approaches to conventional and novel treatment options in the management of AR with nonnasal symptoms will be discussed in this practical, case-based, educational format.
Educational Objectives
After completing this activity, the participant should be better able to:
- Identify the nonnasal symptoms associated with allergic rhinitis (AR)
- Describe action plans to improve the quality of life of patients with AR with nonnasal symptoms
- Outline the relative efficacy of available and novel pharmacotherapies used in the management of patients with AR with nonnasal symptoms
Faculty
Myron J. Zitt, MD
Clinical Associate Professor of Medicine,
State University of New York at Stony Brook
Stony Brook, New York
Director, Adult Allergy Clinic
Nassau University Medical Center
East Meadow, New York
Chief, Allergy-Immunology
Queens Long Island Medical Group,
North Babylon, New York
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Integrity Continuing Education. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Myron J. Zitt, MD
Consulting Fees:Aerocrine, Alcon, Greer Laboratories, Schering Corporation, TEVA Pharmaceuticals, Verus Pharmaceuticals
Fees for Non-CME Services:AstraZeneca, Merck
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Steven A. Henry, MD No real or apparent conflicts of interest to report
Linda Graham, RN, MSN No real or apparent conflicts of interest to report
Method of Participation
There are no fees for participating and receiving CME credit for this activity. During the period January 2008 through December 31, 2008, participants must:
- Read the learning objectives and faculty disclosures
- Study the educational activity
- Complete the posttest by recording the best answer to each question in the answer key on the evaluation form
- Complete the evaluation form
- Mail or fax the evaluation form with answer key to PIM.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within three weeks.
Media
Internet
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, Integrity Continuing Education, and Schering Corporation do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Integrity Continuing Education, or Schering Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|
